Cardarine GW-501516 Guide: Research, Uses and Cycle Information

Cardarine, GW-501516 and GW1516 are names used for the same investigational metabolic compound. It is commonly grouped with SARMs in the performance market, but it does not act through the androgen receptor and is not technically a selective androgen receptor modulator.

What Is Cardarine GW-501516?

GW-501516 is an investigational compound developed as an agonist of peroxisome proliferator-activated receptor delta, commonly abbreviated as PPAR-delta. Cardarine is the name most frequently used within the performance market.

It was originally researched as a potential treatment for abnormal blood lipids, metabolic syndrome, obesity and related cardiovascular risk factors.

GW-501516 is not approved as a fat-loss, endurance or athletic-performance medicine.

Is Cardarine a SARM?

No. Cardarine does not belong to the selective androgen receptor modulator class.

True SARMs such as Ostarine, LGD-4033, RAD-140 and S-4 interact with androgen receptors. Cardarine instead activates PPAR-delta, a nuclear receptor involved in lipid utilization, energy metabolism and gene expression.

Cardarine remains commercially grouped with SARMs because it is sold within the same performance-focused market and appears in many pre-built SARM stacks. That commercial grouping does not make it a SARM.

How Does Cardarine Work?

PPAR-delta is involved in the regulation of genes associated with fatty-acid transport, oxidation, energy expenditure and lipoprotein metabolism.

Activating this receptor can influence how skeletal muscle and other tissues process fatty acids. Human and laboratory studies have reported changes in markers associated with fat oxidation and blood-lipid metabolism.

This mechanism should not be simplified into a guarantee that Cardarine automatically burns body fat or improves athletic performance.

Published Human Research on Cardarine

GW-501516 has been administered to humans in controlled clinical research, although those studies focused on metabolic and lipid outcomes rather than bodybuilding or athletic performance.

A twelve-week randomized study included 268 participants with low HDL cholesterol. Participants received placebo or daily GW-501516 amounts of 2.5 mg, 5 mg or 10 mg.

The researchers reported dose-related changes in several lipid measurements. At the highest studied amount, HDL cholesterol and apolipoprotein A-I increased, while LDL cholesterol, triglycerides, apolipoprotein B and free fatty acids decreased.

These findings established measurable metabolic activity in humans. They did not evaluate running endurance, gym performance, muscle growth or bodybuilding cutting outcomes.

Cardarine Research in Moderately Overweight Men

A smaller two-week randomized study evaluated GW-501516 in moderately overweight men. Six participants received 10 mg daily, while separate groups received placebo or another experimental PPAR compound.

The GW-501516 group recorded reductions in fasting triglycerides, LDL cholesterol, apolipoprotein B, insulin and liver-fat measurements during the short study.

The researchers also observed changes consistent with increased fatty-acid oxidation in skeletal muscle.

This was a very small and short metabolic study. It should not be presented as proof that Cardarine produces a particular amount of whole-body fat loss or visible body recomposition.

Cardarine and Cholesterol Research

Some of the strongest human evidence for GW-501516 relates to blood-lipid measurements rather than athletic outcomes.

The twelve-week trial reported increases in HDL-related measurements and reductions in several LDL, triglyceride and apolipoprotein measurements.

These results were obtained in selected research populations under controlled conditions. They do not establish Cardarine as an approved treatment for high cholesterol or cardiovascular disease.

Why Cardarine Is Discussed for Endurance

Cardarine became associated with endurance after animal studies examined how PPAR-delta activation affected oxidative muscle fibres and running performance.

In a frequently cited mouse study, GW-501516 combined with exercise training increased oxidative muscle adaptation and running endurance compared with exercise training alone.

That research involved mice, not trained human athletes. There is no equivalent controlled human trial proving that Cardarine increases running distance, stamina or competitive performance by a specific amount.

The term “exercise mimetic” describes experimental biological pathways and should not be interpreted as meaning that Cardarine replaces physical training.

Cardarine and Fat-Loss Claims

GW-501516 has been studied for its effects on fatty-acid oxidation, liver-fat measurements and metabolic markers. This research led to widespread performance-market claims about cutting and fat loss.

However, increased fatty-acid oxidation is not identical to guaranteed loss of stored body fat. Body weight and body-fat changes remain strongly influenced by calorie intake, diet adherence, activity and training.

The available human studies were not designed to prove a specific visible fat-loss result in healthy recreational users.

Cardarine and Muscle Growth

Cardarine is not an anabolic androgen receptor modulator and should not be described as a direct muscle-building compound.

Its research history relates primarily to lipid metabolism, fatty-acid oxidation and metabolic markers rather than increases in lean body mass.

Any claim that Cardarine directly builds muscle would require evidence that is not provided by the established human metabolic studies.

Common Cardarine Cycle Discussions

Performance communities commonly discuss Cardarine use in the 10–20 mg daily range for periods of approximately six to eight weeks.

These are non-medical community patterns rather than clinically validated performance protocols. Human metabolic studies used different research designs, populations and monitoring standards.

The fact that an amount has been discussed online does not establish its safety, effectiveness or suitability for an individual user.

Does Cardarine Require PCT?

Cardarine does not activate the androgen receptor and is not generally associated with testosterone suppression through the same mechanism as genuine SARMs.

For that reason, Cardarine used alone is not normally the compound driving SARM PCT discussions.

Cardarine is frequently combined with suppressive SARMs such as RAD-140, LGD-4033 or Ostarine. When it is used within a stack, post-cycle considerations relate primarily to the androgen-receptor compounds included in that combination.

Available post-cycle products can be compared in the SARM PCT and Post-Cycle Support category.

Cardarine Compared With Ostarine

Cardarine and Ostarine are commonly sold together, but they belong to different compound classes.

Ostarine MK-2866 is a selective androgen receptor modulator with human research involving lean body mass and physical function.

Cardarine is a PPAR-delta agonist with human research focused mainly on lipid metabolism and metabolic markers.

The Sarms Thailand Cardarine product contains 20 mg per ml, while the Ostarine product contains 25 mg per ml. The concentrations cannot be used to compare potency because the compounds work through different biological pathways.

Cardarine Compared With MK-677

Cardarine and MK-677 are both commonly grouped with SARMs commercially, but neither compound is technically a SARM.

MK-677 Ibutamoren is a ghrelin-receptor agonist and growth-hormone secretagogue. Cardarine activates PPAR-delta and is researched primarily in relation to lipid and energy metabolism.

They should not be presented as interchangeable compounds or as different versions of the same product.

Cardarine in SARM Stacks

Cardarine appears in several pre-built packages, including stacks positioned around cutting, beach-body goals and combat-sport performance.

Some combinations also contain RAD-140, Ostarine or MK-677. Only RAD-140 and Ostarine are genuine SARMs within those examples.

Combining several compounds creates a more complex cycle than using one product alone. Each ingredient should be reviewed according to its own mechanism, evidence base and monitoring considerations.

Available packages can be compared in the SARM Stacks in Thailand category.

Preclinical Toxicology and Development Status

Development of GW-501516 was discontinued after serious toxicity findings were identified during long-term preclinical animal studies.

Animal toxicology findings do not establish a quantified cancer risk in humans, but they are a material part of Cardarine’s research history and should not be omitted when discussing the compound.

There are no long-term controlled human studies establishing the safety of performance-market Cardarine use.

Cardarine and Anti-Doping Rules

GW-501516 is prohibited under the World Anti-Doping Agency category for hormone and metabolic modulators.

It may also be identified as GW1516, GW-501516 or Cardarine in anti-doping information. Athletes subject to drug testing should avoid products containing these identifiers.

Frequently Asked Questions

Are Cardarine, GW-501516 and GW1516 the same compound?

Yes. Cardarine is the familiar market name, while GW-501516 and GW1516 are research identifiers associated with the same compound.

Is Cardarine a real SARM?

No. Cardarine is a PPAR-delta agonist and metabolic modulator. It does not belong to the selective androgen receptor modulator class.

Has Cardarine been studied in humans?

Yes. Controlled human studies examined cholesterol, triglycerides, liver fat, insulin and other metabolic measurements. They were not athletic-performance or bodybuilding trials.

Has Cardarine been proven to increase endurance in humans?

No controlled human athletic trial has established a specific endurance improvement. The most frequently cited endurance findings came from mouse research.

Does Cardarine directly burn body fat?

Research has reported changes in fatty-acid oxidation and selected metabolic measurements, but this does not prove a guaranteed reduction in whole-body fat for every user.

How much Cardarine is in 1 ml?

In a liquid containing 20 mg per ml, one full millilitre contains 20 mg of GW-501516.

Does Cardarine require SARM PCT?

Cardarine does not act through the androgen receptor and is not normally the compound responsible for SARM-related testosterone suppression. When combined with genuine SARMs, post-cycle considerations relate mainly to those androgen-receptor compounds.

Cardarine Research Sources

• Twelve-week GW-501516 lipid study in 268 participants
• Two-week GW-501516 metabolic study in moderately overweight men
• Early human PPAR-delta agonist study
• Mouse research on PPAR-delta activation, exercise adaptation and endurance
• ClinicalTrials.gov GW-501516 lipid-study record
• World Anti-Doping Agency GW-501516 alert
• World Anti-Doping Agency Prohibited List